Spinraza™ (nusinersen)

I. Length of Authorization

Coverage will be provided annually and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [Pharmacy Benefit]:
   - Loading: 1 vial on D1, D15, D29, and D59
   - Maintenance: 1 vial every 112 days

B. Max Units (per dose and over time) [Medical Benefit]:
   - Loading: 12 mg on D1, D15, D29, and D59
   - Maintenance: 12 mg every 112 days
     - C9489/J2326: 120 BU per administration*

III. Initial Approval Criteria

Coverage is provided in the following conditions:

Spinal Muscular Atrophy (SMA) †

- Patient must have the following laboratory tests at baseline and prior to each administration*: platelet count, prothrombin time; activated partial thromboplastin time, and quantitative spot urine protein testing; AND
- Patient retains meaningful voluntary motor function (e.g. manipulate objects using upper extremities, ambulate, etc.); AND
- Patient must have a diagnosis of 5q spinal muscular atrophy confirmed by either homozygous deletion of the SMN1 gene or dysfunctional mutation of the SMN1 gene; AND
- Patient must have one of the following SMA phenotypes; AND
  - SMA I
o SMA II with symptomatic disease (i.e. impaired motor function and/or delayed motor milestones)

o SMA III with symptomatic disease (i.e. impaired motor function and/or delayed motor milestones)

- Baseline documentation of one or more of the following:
  
o Motor function/milestones, including but not limited to, the following validated scales: Hammersmith Infant Neurologic Exam (HINE), Hammersmith Functional Motor Scale Expanded (HFMSE), 6-minute walk test (6MWT), upper limb module (ULM), etc.
  
o Respiratory function tests [e.g., forced vital capacity (FVC), etc.]
  
o Exacerbations necessitating hospitalization and/or antibiotic therapy for respiratory infection in the preceding year/timeframe
  
o Patient weight (for patients without a gastrostomy tube)

† FDA-labeled indication(s)

*Laboratory tests should be obtained within several days prior to administration

IV. Renewal Criteria

- Patient continues to meet the criteria in Section III: **AND**
- Absence of unacceptable toxicity which would preclude safe administration of the drug. Examples of unacceptable toxicity include the following: significant renal toxicity, thrombocytopenia, coagulation abnormalities, etc.: **AND**
- Patient has responded to therapy compared to pretreatment baseline in one or more of the following:
  
o Stability or improvement in net motor function/milestones, including but not limited to, the following validated scales: Hammersmith Infant Neurologic Exam (HINE), Hammersmith Functional Motor Scale Expanded (HFMSE), 6-minute walk test (6MWT), upper limb module (ULM), etc.
  
o Stability or improvement in respiratory function tests [e.g., forced vital capacity (FVC), etc.]
  
o Reduction in exacerbations necessitating hospitalization and/or antibiotic therapy for respiratory infection in the preceding year/timeframe
  
o Stable or increased patient weight (for patients without a gastrostomy tube)
  
o Improvement/slowed rate of decline in the aforementioned measures

V. Dosage/Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
</table>

Spinraza™ (nusinersen) Prior Auth Criteria
Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
©2017, Magellan Rx Management
<table>
<thead>
<tr>
<th>Spinal Muscular Atrophy</th>
<th>12 mg administered as an intrathecal bolus injection per administration. Prior to administration, 5 mL of cerebrospinal fluid should be removed. Imaging guidance and sedation may be required for administration.</th>
</tr>
</thead>
</table>
|                        | **Initiation**  
|                        | Four loading doses: the first three loading doses should be administered at 14-day intervals. The 4th loading dose should be administered 30 days after the 3rd dose.  
|                        | **Maintenance**  
|                        | One dose every 4 months thereafter  
|                        | Store refrigerated at 2°C to 8°C; warm to room temperature prior to administration |

**VI. Billing Code/Availability Information**

**Jcode:**
- J3490 – Unclassified drugs
- J3590 – Unclassified biologics
- C9489 - Injection, nusinersen, 0.1 mg (∗Effective 7/1/17)
- J2326 - Injection, nusinersen, 0.1 mg (∗Effective 1/1/18)

**NDC:**
Spinraza 12 mg/5 mL solution for injection: single-dose vial: 64406-0058-xx

**VII. References**

**Appendix 1 – Covered Diagnosis Codes**

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G12.0</td>
<td>Infantile spinal muscular atrophy, type I [Werdnig-Hoffmann]</td>
</tr>
<tr>
<td>G12.1</td>
<td>Other inherited spinal muscular atrophy</td>
</tr>
<tr>
<td>G12.25</td>
<td>Progressive spinal muscle atrophy</td>
</tr>
<tr>
<td>G12.8</td>
<td>Other spinal muscular atrophies and related syndromes</td>
</tr>
<tr>
<td>G12.9</td>
<td>Spinal muscular atrophy, unspecified</td>
</tr>
</tbody>
</table>
Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

- N/A

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Applicable State/US Territory</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>E (1)</td>
<td>CA, HI, NV, AS, GU, CNMI</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>F (2 &amp; 3)</td>
<td>AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>5</td>
<td>KS, NE, IA, MO</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>6</td>
<td>MN, WI, IL</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>H (4 &amp; 7)</td>
<td>LA, AR, MS, TX, OK, CO, NM</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>8</td>
<td>MI, IN</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>N (9)</td>
<td>FL, PR, VI</td>
<td>First Coast Service Options, Inc.</td>
</tr>
<tr>
<td>J (10)</td>
<td>TN, GA, AL</td>
<td>Cahaba Government Benefit Administrators, LLC</td>
</tr>
<tr>
<td>M (11)</td>
<td>NC, SC, WV, VA (excluding below)</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>L (12)</td>
<td>DE, MD, PA, NJ, DC (includes Arlington &amp; Fairfax counties and the city of Alexandria in VA)</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>K (13 &amp; 14)</td>
<td>NY, CT, MA, RI, VT, ME, NH</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>15</td>
<td>KY, OH</td>
<td>CGS Administrators, LLC</td>
</tr>
</tbody>
</table>